Incidence Differences Between First Primary Cancers and Second Primary Cancers Following Skin Squamous Cell Carcinoma as Etiological Clues

. 2020 ; 12 () : 857-864. [epub] 20200806

Status PubMed-not-MEDLINE Jazyk angličtina Země Nový Zéland Médium electronic-ecollection

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid32821171

BACKGROUND: Most literature on second primary cancers (SPCs) focuses on possible factors, which may increase the risk of these cancers, and little attention has been paid for the overall incidence differences between first primary cancers (FPCs) and same SPCs. We wanted to compare the incidence rates for all common cancers when these were diagnosed as FPCs and SPCs after invasive and in situ squamous cell carcinoma (SCC) of the skin, which are usually treated by surgery only. METHODS: Cancers were identified from the Swedish Cancer Registry from the years 1990 through to 2015, and they included, in addition to skin cancers, 20 male cancers totaling 484,850 patients and 22 female cancers totaling 452,909 patients. Standardized incidence rates and relative risks (RRs) were calculated for sex-specific common cancers as FPC and as SPC after skin SCC. Spearman rank correlations were used in the analysis of incidence ranking of FPC and SPC. RESULTS: Of total, 29,061 men and 23,533 women developed invasive SCC and 27,842 men and 36,383 women in situ SCC. The total number of 20 other male cancers was 484,850 and of 22 female cancers it was 452,909. Rank correlations ranged from 0.90 to 0.96 (P~5×10-6), indicating that overall skin SCC did not interfere with SPC formation. The exceptions were increased SPC risks for melanoma, sharing risk factors with skin SCC, and non-Hodgkin and Hodgkin lymphoma, and cancers of the upper aerodigestive tract, connective tissue, and male and female genitals suggesting contribution by skin cancer initiated immune dysfunction. CONCLUSION: The incidence ranking of SPCs after skin cancers largely follows the incidence ranking of FPCs indicating that overall skin SCC does not greatly interfere with the intrinsic carcinogenic process. The main deviations in incidence between FPC and SPC appeared to be due to shared risk factors or immunological processes promoting immune responsive cancer types.

Zobrazit více v PubMed

Vogt A, Schmid S, Heinimann K, et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017;2(2):e000172. doi:10.1136/esmoopen-2017-000172 PubMed DOI PMC

Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 2013;10(5):289–301. doi:10.1038/nrclinonc.2013.41 PubMed DOI

Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship–genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98:15–25. doi:10.1093/jnci/djj001 PubMed DOI

Chattopadhyay S, Zheng G, Hemminki O, Forsti A, Sundquist K, Hemminki K. Prostate cancer survivors: risk and mortality in second primary cancers. Cancer Med. 2018;7(11):5752–5759. doi:10.1002/cam4.1764 PubMed DOI PMC

Chattopadhyay S, Hemminki A, Försti A, Sundquist K, Sundquist J, Hemmiinki K. Familial risks and mortality in second primary cancers in melanoma. JNCI Cancer Spectr. 2019;2:pky068. doi:10.1093/jncics/pky068 PubMed DOI PMC

Chattopadhyay S, Hemminki O, Forsti A, Sundquist K, Sundquist J, Hemminki K. Impact of family history of cancer on risk and mortality of second cancers in patients with prostate cancer. Prostate Cancer Prostatic Dis. 2018. PubMed

Centre for Epidemiology. Cancer Incidence in Sweden 2012. Stockholm: The National Board of Health and Welfare; 2013.

Green AC, Olsen CM. Cutaneous squamous cell carcinoma: an epidemiological review. Br J Dermatol. 2017;177(2):373–381. doi:10.1111/bjd.15324 PubMed DOI

IARC. Personal Habits and Indoor Combustions, Vol. 100E. Lyon: International Agency for Research on Cancer; 2012:575.

Omland SH, Ahlstrom MG, Gerstoft J, et al. Risk of skin cancer in patients with HIV: a Danish nationwide cohort study. J Am Acad Dermatol. 2018;79(4):689–695. doi:10.1016/j.jaad.2018.03.024 PubMed DOI

Hortlund M, Arroyo Muhr LS, Storm H, Engholm G, Dillner J, Bzhalava D. Cancer risks after solid organ transplantation and after long-term dialysis. Int J Cancer. 2017;140(5):1091–1101. doi:10.1002/ijc.30531 PubMed DOI

Harwood CA, Toland AE, Proby CM, et al. The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients. Br J Dermatol. 2017;177(5):1217–1224. doi:10.1111/bjd.15956 PubMed DOI

Bottomley MJ, Thomson J, Harwood C, Leigh I. The role of the immune system in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019;20(8):2009. doi:10.3390/ijms20082009 PubMed DOI PMC

Ji J, Sundquist K, Sundquist J, Hemminki K. Comparability of cancer identification among death registry, cancer registry and hospital discharge registry. Int J Cancer. 2012;131:2085–2093. doi:10.1002/ijc.27462 PubMed DOI

Pukkala E, Engholm G, Hojsgaard Schmidt LK, et al. Nordic cancer registries - an overview of their procedures and data comparability. Acta Oncol. 2018;57:440–455. doi:10.1080/0284186X.2017.1407039 PubMed DOI

Chen T, Fallah M, Brenner H, et al. Risk of second primary cancers in multiple myeloma survivors in german and swedish cancer registries. Sci Rep. 2016;6:22084. doi:10.1038/srep22084 PubMed DOI PMC

Chen T, Fallah M, Jansen L, et al. Distribution and risk of the second discordant primary cancers combined after a specific first primary cancer in German and Swedish cancer registries. Cancer Lett. 2015;369(1):152–166. doi:10.1016/j.canlet.2015.08.014 PubMed DOI

Chattopadhyay S, Hemminki A, Forsti A, Sundquist K, Sundquist J, Hemminki K. Second primary cancers in patients with invasive and in situ squamous cell skin carcinoma, Kaposi sarcoma and Merkel cell carcinoma: role for immune mechanisms? J Invest Dermatol. 2019. PubMed

Chattopadhyay S, Sud A, Zheng G, et al. Second primary cancers in non-Hodgkin lymphoma: bi-directional analyses suggesting role for immune dysfunction. Int J Cancer. 2018;143:2449–2457. doi:10.1002/ijc.31801 PubMed DOI

Hemminki K, Hemminki O, Försti A, Sundquist K, Sundquist J, Li X. Surveillance bias in cancer risk after unrelated medical conditions: example urolithiasis. Sci Rep. 2017;7:8073. doi:10.1038/s41598-017-08839-5 PubMed DOI PMC

Emens LA, Ascierto PA, Darcy PK, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116–129. doi:10.1016/j.ejca.2017.01.035 PubMed DOI

Rama I, Grinyo JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol. 2010;6(9):511–519. doi:10.1038/nrneph.2010.102 PubMed DOI

Harms PW, Harms KL, Moore PS, et al. The biology and treatment of Merkel cell carcinoma: current understanding and research priorities. Nat Rev Clin Oncol. 2018;15(12):763–776. doi:10.1038/s41571-018-0103-2 PubMed DOI PMC

Rangwala S, Tsai KY. Roles of the immune system in skin cancer. Br J Dermatol. 2011;165(5):953–965. doi:10.1111/j.1365-2133.2011.10507.x PubMed DOI PMC

Zur Hausen H. The search for infectious causes of human cancers: where and why. Virology. 2009;392:1–10. doi:10.1016/j.virol.2009.06.001 PubMed DOI

IARC. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1–441. PubMed PMC

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace